Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant gemcitabine + docetaxel followed by doxorubicin versus observation in uterus-limited high-grade uterine leiomyosarcoma
2012-002852-17Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 2013
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, docetaxel and doxorubicin in uterine leiomyosarcoma (uLMS) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall survival. Started Jan 2013; status: terminated.
02
Drugs
gemcitabinedocetaxeldoxorubicin
03
Conditions
uterine leiomyosarcoma (uLMS)
Beyond the preview
Go deeper on 2012-002852-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002852-17.